PIPELINE
Focused on a high-stakes need.
Investigational product
Our lead program is in Phase 2 U.S. clinical development for anticoagulant reversal.
CLINICAL PROGRAM
PW-977
Ciraparantag
Investigational small-molecule anticoagulant reversal agent
Phase 1Phase 2Phase 3Approval
CURRENT DEVELOPMENT FOCUS
Major bleeding
Development is focused on reversal of factor Xa inhibitor anticoagulation in patients with major bleeding when medically indicated.
Development stagePhase 2
AdministrationIntravenous
Regulatory statusInvestigational
PW-977 is an investigational drug. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established.